Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of ursodeoxycholic acid in the treatment of insulin resistance and vascular dysfunction in non-alcoholic fatty liver disease
2007-004515-56Phase 3Terminated
- Sponsor
- Medical University of Vienna, Department of Internal Medicine IV
- Start
- Mar 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease (MASLD), insulin resistance (IR) and vascular dysfunction, sponsored by Medical University of Vienna, Department of Internal Medicine IV. Primary endpoints: Insulin resistance and Vascular dysfunction. Started Mar 2008; status: terminated.
02
Drugs
ursodeoxycholic acid
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)insulin resistance (IR)vascular dysfunction
Beyond the preview
Go deeper on 2007-004515-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004515-56.